Cerebral venous sinus thrombosis
|Cerebral venous sinus thrombosis|
|Other names||Cerebral venous and sinus thrombosis, (superior) sagittal sinus thrombosis, dural sinus thrombosis, intracranial venous thrombosis, cerebral thrombophlebitis|
|Treatment||Low molecular weight heparin|
Cerebral venous sinus thrombosis (CVST) is the presence of a blood clot in the dural venous sinuses, which drain blood from the brain. Symptoms may include headache, abnormal vision, any of the symptoms of stroke such as weakness of the face and limbs on one side of the body, and seizures.
The diagnosis is usually by computed tomography (CT scan) or magnetic resonance imaging (MRI) to demonstrate obstruction of the venous sinuses. Testing may be done to try to determine the underlying cause.
Treatment is typically with anticoagulants (medication that suppresses blood clotting) such as low molecular weight heparin. Rarely, thrombolysis (enzymatic destruction of the blood clot) is used. The disease may be complicated by raised intracranial pressure, which may warrant surgical intervention such as the placement of a shunt.
Signs and symptoms
Nine in ten people with sinus thrombosis have a headache; this tends to worsen over the period of several days, but may also develop suddenly (thunderclap headache). The headache may be the only symptom of cerebral venous sinus thrombosis. Many patients have symptoms of stroke: inability to move one or more limbs, weakness on one side of the face or difficulty speaking. This does not necessarily affect one side of the body as in the more common "arterial" stroke.
40% of people have seizures, although it is more common in women who develop sinus thrombosis peripartum (in the period before and after giving birth). These are mostly seizures affecting only one part of the body and unilateral (occurring on one side), but occasionally the seizures are generalised and rarely they lead to status epilepticus (persistent or recurrent seizure activity for a long period of time).
In the elderly, many of the aforementioned symptoms may not occur. Common symptoms in the elderly with this condition are otherwise unexplained changes in mental status and a depressed level of consciousness.
The pressure around the brain may rise, causing papilledema (swelling of the optic disc) which may be experienced as visual obscurations. In severely raised intracranial pressure, the level of consciousness is decreased, the blood pressure rises, the heart rate falls and the patient assumes an abnormal posture.
Cerebral venous sinus thrombosis is more common in particular situations. 85% of people have at least one of these risk factors:
- Thrombophilia, a tendency to develop blood clots due to abnormalities in coagulation, e.g. factor V Leiden, deficiency of protein C, protein S or antithrombin, or related problems
- Nephrotic syndrome, a kidney problem causing protein loss in the urine
- Chronic inflammatory diseases, such as inflammatory bowel disease, lupus and Behçet's disease
- Pregnancy and puerperium (the period after giving birth)
- Particular blood disorders, especially polycythemia vera and paroxysmal nocturnal hemoglobinuria
- Use of estrogen-containing forms of hormonal contraception
- Meningitis and infections of the ear, nose and throat area such as mastoiditis and sinusitis
- Direct injury to the venous sinuses
- Medical procedures in the head and neck area
- Sickle cell anemia
- Dehydration, primarily in infants and children
The diagnosis may be suspected on the basis of the symptoms, for example the combination of headache, signs of raised intracranial pressure and focal neurological abnormalities, or when alternative causes of headache and neurological abnormalities, such as a subarachnoid hemorrhage, have been excluded.
There are various neuroimaging investigations that may detect cerebral sinus thrombosis. Cerebral edema and venous infarction may be apparent on any modality, but for the detection of the thrombus itself, the most commonly used tests are computed tomography (CT) and magnetic resonance imaging (MRI), both using various types of radiocontrast to perform a venogram and visualise the veins around the brain.
Computed tomography, with radiocontrast in the venous phase (CT venography or CTV), has a detection rate that in some regards exceeds that of MRI. The test involves injection into a vein (usually in the arm) of a radioopaque substance, and time is allowed for the bloodstream to carry it to the cerebral veins - at which point the scan is performed. It has a sensitivity of 75-100% (it detects 75-100% of all clots present), and a specificity of 81-100% (it would be incorrectly positive in 0-19%). In the first two weeks, the "empty delta sign" may be observed (in later stages, this sign may disappear).
Magnetic resonance venography employs the same principles, but uses MRI as a scanning modality. MRI has the advantage of being better at detecting damage to the brain itself as a result of the increased pressure on the obstructed veins, but it is not readily available in many hospitals and the interpretation may be difficult.
Cerebral angiography may demonstrate smaller clots than CT or MRI, and obstructed veins may give the "corkscrew appearance". This, however, requires puncture of the femoral artery with a sheath and advancing a thin tube through the blood vessels to the brain where radiocontrast is injected before X-ray images are obtained. It is therefore only performed if all other tests give unclear results or when other treatments may be administered during the same procedure.
In most patients, the direct cause for the cerebral sinus thrombosis is not readily apparent. Identifying a source of infection is crucial; it is common practice to screen for various forms of thrombophilia (a propensity to form blood clots).
The veins of the brain, both the superficial veins and the deep venous system, empty into the dural venous sinuses, which carry blood back to the jugular vein and thence to the heart. In cerebral venous sinus thrombosis, blood clots usually form both in the veins of the brain and the venous sinuses. The thrombosis of the veins themselves causes venous infarction—damage to brain tissue due to a congested and therefore insufficient blood supply. This results in cerebral edema (both vasogenic and cytotoxic edema), and leads to small petechial haemorrhages that may merge into large haematomas. Thrombosis of the sinuses is the main mechanism behind the increase in intracranial pressure due to decreased resorption of cerebrospinal fluid (CSF). The condition does not lead to hydrocephalus, however, because there is no difference in pressure between various parts of the brain.
Any blood clot forms due to an imbalance between coagulation (the formation of the insoluble blood protein fibrin) and fibrinolysis. The three major mechanisms for such an imbalance are enumerated in Virchow's triad: alterations in normal blood flow, injury to the blood vessel wall, and alterations in the constitution of blood (hypercoagulability). Most cases of cerebral venous sinus thrombosis are due to hypercoagulability.
It is possible for the clot to break off and migrate (embolise) to the lungs, causing a pulmonary embolism. An analysis of earlier case reports concludes that this occurs in about 10% of cases, but has a very poor prognosis.
Various studies have investigated the use of anticoagulation to suppress blood clot formation in cerebral venous sinus thrombosis. Before these trials had been conducted, there had been a concern that small areas of hemorrhage in the brain would bleed further as a result of treatment; the studies showed that this concern was unfounded. Clinical practice guidelines now recommend heparin or low molecular weight heparin in the initial treatment, followed by warfarin, provided there are no other bleeding risks that would make these treatments unsuitable. Some experts discourage the use of anticoagulation if there is extensive hemorrhage; in that case, they recommend repeating the imaging after 7–10 days. If the hemorrhage has decreased in size, anticoagulants are started, while no anticoagulants are given if there is no reduction.
The duration of warfarin treatment depends on the circumstances and underlying causes of the condition. If the thrombosis developed under temporary circumstances (e.g. pregnancy), three months are regarded as sufficient. If the condition was unprovoked but there are no clear causes or a "mild" form of thrombophilia, 6 to 12 months is advised. If there is a severe underlying thrombosis disorder, warfarin treatment may need to continue indefinitely.
Thrombolysis (removal of the blood clot with "clot buster" medication) has been described, either systemically by injection into a vein or directly into the clot during angiography. The 2006 European Federation of Neurological Societies guideline recommends that thrombolysis is only used in patients who deteriorate despite adequate treatment, and other causes of deterioration have been eliminated. It is unclear which drug and which mode of administration is the most effective. Bleeding into the brain and in other sites of the body is a major concern in the use of thrombolysis. American guidelines make no recommendation with regards to thrombolysis, stating that more research is needed.
In those where a venous infarct or hemorrhage causes significant compression of surrounding brain structures, decompressive craniectomy is sometimes required. Raised intracranial pressure, if severe or threatening vision, may require therapeutic lumbar puncture (removal of excessive cerebrospinal fluid), medication (acetazolamide), or neurosurgical treatment (optic nerve sheath fenestration or shunting). In certain situations, anticonvulsants may be used to try to prevent seizures. These situations include focal neurological problems (e.g. inability to move a limb) and focal changes of the brain tissue on CT or MRI scan. Evidence to support or refute the use of antiepileptic drugs as a preventive measure, however, is lacking.
In 2004 the first adequately large scale study on the natural history and long-term prognosis of this condition was reported; this showed that at 16 months follow-up 57.1% of patients had full recovery, 29.5%/2.9%/2.2% had respectively minor/moderate/severe symptoms or impairments, and 8.3% had died. Severe impairment or death were more likely in those aged over 37 years, male, affected by coma, mental status disorder, intracerebral hemorrhage, thrombosis of the deep cerebral venous system, central nervous system infection and cancer. A subsequent systematic review of nineteen studies in 2006 showed that mortality is about 5.6% during hospitalisation and 9.4% in total, while of the survivors 88% make a total or near-total recovery. After several months, two thirds of the cases has resolution ("recanalisation") of the clot. The rate of recurrence was low (2.8%).
Cerebral venous sinus thrombosis is rare, with an estimated 3-4 cases per million annual incidence in adults. While it may occur in all age groups, it is most common in the third decade. 75% are female. Given that older studies show no difference in incidence between men and women, it has been suggested that the use of oral contraceptives in women is behind the disparity between the sexes. A 1995 report from Saudi Arabia found a doubled incidence at 7 cases per 100,000; this was attributed to the fact that Behçet's disease, which increases risk of CVST, is more common in the Middle East.
A 1973 report found that CVST could be found on autopsy (examination of the body after death) in nine percent of all people. Many of these were elderly and had neurological symptoms in the period leading up to their death, and many suffered from concomitant heart failure.
In children, a Canadian study reported in 2001 that CVST occurs in 6.7 per million annually. 43% occur in the newborn (less than one month old), and a further 10% in the first year of life. Of the newborn, 84% were already ill, mostly from complications after childbirth and dehydration.
The first description of thrombosis of the cerebral veins and sinuses is attributed to the French physician Ribes, who in 1825 observed thrombosis of the sagittal sinus and cerebral veins in a man who had suffered from seizures and delirium. Until the second half of the 20th century it remained a diagnosis generally made after death. In the 1940s, reports by Dr Charles Symonds and others allowed for the clinical diagnosis of cerebral venous thrombosis, using characteristic signs and symptoms and results of lumbar puncture.
Improvements on the diagnosis of cerebral venous sinus thrombosis in life were made with the introduction of venography in 1951, which also aided in the distinction from idiopathic intracranial hypertension, which has similar presenting signs and symptoms in many cases.
The British gynecologist Stansfield is credited with the introduction, in 1942, of the just recently introduced anticoagulant heparin in the treatment of CVST in 1942. Clinical trials in the 1990s finally resolved the concern about using anticoagulants in most cases of CVST.
U.S. Secretary of State Hillary Clinton was hospitalized on December 30, 2012, for anticoagulation treatment of venous thrombosis of the right transverse sinus, which is located at the base of the brain. Clinton's thrombotic episode was discovered on an MRI scan done for follow-up of a cerebral concussion she had suffered 2.5 weeks before after she fell while suffering from gastroenteritis.
- Al Rawahi, B; Almegren, M; Carrier, M (September 2018). "The efficacy and safety of anticoagulation in cerebral vein thrombosis: A systematic review and meta-analysis". Thrombosis Research. 169: 135–139. doi:10.1016/j.thromres.2018.07.023. PMID 30056293.
- Stam J (2005). "Thrombosis of the cerebral veins and sinuses". N. Engl. J. Med. 352 (17): 1791–8. doi:10.1056/NEJMra042354. PMID 15858188.
- Cumurciuc R, Crassard I, Sarov M, Valade D, Bousser MG (2005). "Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 cases". J. Neurol. Neurosurg. Psychiatry. 76 (8): 1084–7. doi:10.1136/jnnp.2004.056275. PMC 1739763. PMID 16024884.
- Einhäupl K, Bousser MG, de Bruijn SF, et al. (2006). "EFNS guideline on the treatment of cerebral venous and sinus thrombosis". Eur. J. Neurol. 13 (6): 553–9. doi:10.1111/j.1468-1331.2006.01398.x. PMID 16796579.
- Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F (2005). "Cerebral vein and dural sinus thrombosis in elderly patients". Stroke. 36 (9): 1927–32. doi:10.1161/01.STR.0000177894.05495.54. PMID 16100024.
- Smith R, Hourihan MD (2007). "Investigating suspected cerebral venous thrombosis". BMJ. 334 (7597): 794–5. doi:10.1136/bmj.39154.636968.47. PMC 1852020. PMID 17431266.
- Smith, E; Kumar, V (June 2018). "BET 1: Does a normal D-dimer rule out cerebral venous sinus thrombosis (CVST)?". Emergency Medicine Journal. 35 (6): 396–397. doi:10.1136/emermed-2018-207777.1. PMID 29784833.
- Diaz JM, Schiffman JS, Urban ES, Maccario M (1992). "Superior sagittal sinus thrombosis and pulmonary embolism: a syndrome rediscovered". Acta Neurol. Scand. 86 (4): 390–6. doi:10.1111/j.1600-0404.1992.tb05106.x. PMID 1455986.
- Coutinho, Jonathan; de Bruijn, Sebastiaan Ftm; Deveber, Gabrielle; Stam, Jan (10 August 2011). "Anticoagulation for cerebral venous sinus thrombosis". Cochrane Database of Systematic Reviews (8): CD002005. doi:10.1002/14651858.CD002005.pub2. ISSN 1469-493X. PMID 21833941.
- National Institute for Health and Clinical Excellence. Clinical guideline 68: Stroke. London, 2008.
- Sacco RL, Adams R, Albers G, et al. (March 2006). "Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline". Circulation. 113 (10): e409–49. doi:10.1161/01.STR.0000199147.30016.74. PMID 16534023.
- Martinelli I, Franchini M, Mannucci PM (September 2008). "How I treat rare venous thromboses". Blood. 112 (13): 4818–23. doi:10.1182/blood-2008-07-165969. PMID 18805965.
- Avanali, Raghunath; Gopalakrishnan, M. S.; Devi, B. Indira; Bhat, Dhananjaya I.; Shukla, Dhaval P.; Shanbhag, Nagesh C. (15 May 2019). "Role of Decompressive Craniectomy in the Management of Cerebral Venous Sinus Thrombosis". Frontiers in Neurology. 10: 511. doi:10.3389/fneur.2019.00511. PMC 6529953. PMID 31156540.
- Price, Michelle; Günther, Albrecht; Kwan, Joseph SK (21 April 2016). "Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis". Cochrane Database of Systematic Reviews. 4: CD005501. doi:10.1002/14651858.cd005501.pub4. hdl:10722/226344. PMID 27098266.
- Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F (2004). "Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)". Stroke. 35 (3): 664–70. doi:10.1161/01.STR.0000117571.76197.26. PMID 14976332.
- Dentali F, Gianni M, Crowther MA, Ageno W (2006). "Natural history of cerebral vein thrombosis: a systematic review". Blood. 108 (4): 1129–34. doi:10.1182/blood-2005-12-4795. PMID 16609071.
- Jackson, BF; Porcher, FK; Zapton, DT; Losek, JD (September 2011). "Cerebral sinovenous thrombosis in children: diagnosis and treatment". Pediatr. Emerg. Care. 27 (9): 874–80, quiz 881–3. doi:10.1097/PEC.0b013e31822c9ccc. PMID 21926891.
- deVeber G, Andrew M, Adams C, et al. (August 2001). "Cerebral sinovenous thrombosis in children". N. Engl. J. Med. 345 (6): 417–23. doi:10.1056/NEJM200108093450604. PMID 11496852.
- Daif A, Awada A, al-Rajeh S, et al. (1 July 1995). "Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia". Stroke. 26 (7): 1193–5. doi:10.1161/01.str.26.7.1193. PMID 7604412.
- Towbin A (1 May 1973). "The syndrome of latent cerebral venous thrombosis: its frequency and relation to age and congestive heart failure". Stroke. 4 (3): 419–30. doi:10.1161/01.str.4.3.419. PMID 4713031.
- Ribes MF (1825). "Des recherches faites sur la phlebite". Rev. Med. Fr. Etrang. 3: 5–41.
- Bousser MG, Chiras J, Bories J, Castaigne P (1 March 1985). "Cerebral venous thrombosis--a review of 38 cases". Stroke. 16 (2): 199–213. doi:10.1161/01.str.16.2.199. PMID 3975957.
- Symonds CP (September 1940). "Cerebral thrombophlebitis". Br. Med. J. 2 (4158): 348–52. doi:10.1136/bmj.2.4158.348. PMC 2179068. PMID 20783290.
- Stansfield FR (April 1942). "Puerperal cerebral thrombophlebitis treated by heparin". Br. Med. J. 1 (4239): 436–438. doi:10.1136/bmj.1.4239.436. PMC 2164893. PMID 20784169.
- Ray BS, Dunbar HS, Dotter CT (January 1951). "Dural sinus venography as an aid to diagnosis in intracranial disease". J. Neurosurg. 8 (1): 23–37. doi:10.3171/jns.1951.8.1.0023. PMID 14804146.
- Ray BS, Dunbar HS (September 1951). "Thrombosis of the dural venous sinuses as a cause of pseudotumor cerebri". Ann. Surg. 134 (3): 376–86. doi:10.1097/00000658-195113430-00009. PMC 1802934. PMID 14869026.
- Paul Richter. "Hillary Clinton expected to make full recovery from blood clot". Los Angeles Times. Retrieved 1 January 2013.
|Wikimedia Commons has media related to Cerebral venous sinus thrombosis.|
- "Intracranial venous thrombosis - Patient UK".
- UCH Institute for Child Health. "Clinical guideline Cerebral Venous Sinus Thrombosis in Children".